Douglas A. Levine

107.1k citations

256 papers · 22.4k indexed · 9 hit papers · h-index 70

Impact in

Reproductive Medicine top 0.02%
- Ovarian cancer diagnosis and treatment
Obstetrics and Gynecology top 0.05%
- Endometrial and Cervical Cancer Treatments

Papers in

Reproductive Medicine 126
- Ovarian cancer diagnosis and treatment 124
Obstetrics and Gynecology 71
- Endometrial and Cervical Cancer Treatments 62
- Uterine Myomas and Treatments 20

Co-authors: Gad Getz Peter W. Laird Hui Shen Scott L. Carter Nadeem R. Abu‐Rustum Gordon B. Mills Richard R. Barakat Emmanuel Martínez
Journals: Gynecologic Oncology (91 papers)Journal of Clinical Oncology (26 papers)Cancer Research (12 papers)Clinical Cancer Research (10 papers)Cancer (8 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Douglas A. Levine

247 papers receiving 22.2k citations

Hit Papers

9 papers align trajectories log scale

Endometrial cancer 2021 · 340 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Nature Reviews Disease Primers
2020 Journal of Clinical Oncology
2018 The American Journal of Surgical Pathology
2013 Nature Communications
2013 Nature Communications
2012 Nature Biotechnology
2009 Gynecologic Oncology
2008 Nature
2006 Gynecologic Oncology

Peers

Countries citing papers authored by Douglas A. Levine

Since Specialization

Citations

This map shows the geographic impact of Douglas A. Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas A. Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas A. Levine more than expected).

Fields of papers citing papers by Douglas A. Levine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas A. Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas A. Levine. The network helps show where Douglas A. Levine may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas A. Levine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas A. Levine Line = papers co-authored together Douglas A. Levine links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Cancer Research Communications ·Funda Meric‐Bernstam, Martin Gutierrez, Enrique Sanz‐García, Diego Villa, Jun Zhang, Jennifer Friedmann, Fengting Yan, Mark A. Socinski, John Sarantopoulos, Luis E. Raez, Quincy S. Chu, Maxime Chénard-Poirier, Manash S. Chatterjee, Hong Ren, Qi Liu, Douglas A. Levine, Komal Jhaveri	2025	1
2	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening Proceedings of the National Academy of Sciences ·Shengqing Gu, Stéphanie Lheureux, Azin Sayad, Paulina Cybulska, Liat Hogen, Iryna Vyarvelska, Dongsheng Tu, Wendy R. Parulekar, Matthew Nankivell, Sean Kehoe, S. Dennis, Douglas A. Levine, Marcus Q. Bernardini, Barry P. Rosen, Amit M. Oza, Myles Brown, Benjamin G. Neel	2021	12
3	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research Carcinogenesis ·Shama Virani, Glauco Baiocchi, David D.L. Bowtell, Citadel J. Cabasag, Kathleen R. Cho, Renée T. Fortner, Keiichi Fujiwara, Jae‐Weon Kim, Martin Köbel, J.E. Kurtz, Douglas A. Levine, Usha Menon, Barbara M. Norquist, Paul D.P. Pharoah, Anil K. Sood, Shelley S. Tworoger, Nicolas Wentzensen, Stephen J. Chanock, Paul Brennan, Britton Trabert	2021	9
4	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer Cancer Discovery ·Shuang Zhang, Sonia Iyer, Hao Ran, Igor Dolgalev, Shengqing Gu, Wei Wei, Connor Foster, Cynthia A. Loomis, Narciso Olvera, Fanny Dao, Douglas A. Levine, Robert A. Weinberg, Benjamin G. Neel	2020	61
5	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines Clinical Cancer Research ·Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P.D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray‐Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, Bernard E. Weissman	2020	84
6	Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma Nature Communications ·Shuang Zhang, Igor Dolgalev, Tao Zhang, Hao Ran, Douglas A. Levine, Benjamin G. Neel	2019	150
7	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers Nature Communications ·Hatice U. Osmanbeyoglu, Fumiko Shimizu, Ángela Rynne‐Vidal, Direna Alonso‐Curbelo, Hsuan-An Chen, Hannah Y. Wen, Tsz-Lun Yeung, Petar Jelinic, Pedram Razavi, Scott W. Lowe, Samuel C. Mok, Gabriela Chiosis, Douglas A. Levine, Christina S. Leslie	2019	18
8	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study Cancer Prevention Research ·Kala Visvanathan, Patricia Shaw, Betty J. May, Asli Bahadirli-Talbott, Alpana Kaushiva, Harvey A. Risch, Steven A. Narod, Tian‐Li Wang, Vinita Parkash, Russell Vang, Douglas A. Levine, Robert A. Soslow, Robert J. Kurman, Ie‐Ming Shih	2018	49
9	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome European Radiology ·Hebert Alberto Vargas, Harini Veeraraghavan, Maura Miccò, Stéphanie Nougaret, Yulia Lakhman, Andreas Meier, Ramon E. Sosa, Robert A. Soslow, Douglas A. Levine, Britta Weigelt, Carol Aghajanian, Hedvig Hricak, Joseph O. Deasy, Alexandra Snyder, Evis Sala	2017	88
10	The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility International Journal of Gynecological Pathology ·Yaser Hussein, Russell R. Broaddus, Britta Weigelt, Douglas A. Levine, Robert A. Soslow	2015	35
11	Endometrial Carcinomas With Clear Cells International Journal of Gynecological Pathology ·Guangming Han, Robert A. Soslow, Stephanie L. Wethington, Douglas A. Levine, Faina Bogomolniy, Philip B. Clement, Martin Köbel, C. Blake Gilks, Deborah F. DeLair	2015	33
12	New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair Molecular Cancer Therapeutics ·Petar Jelinic, Douglas A. Levine	2014	65
13	Blocking and Randomization to Improve Molecular Biomarker Discovery Clinical Cancer Research ·Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, Douglas A. Levine	2014	17
14	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations Clinical Cancer Research ·Joshy George, Kathryn Alsop, Dariush Etemadmoghadam, Heather Hondow, Thomas Mikeska, Alexander Dobrovic, Anna DeFazio, (unknown), Gordon K. Smyth, Douglas A. Levine, Gillian Mitchell, David D.L. Bowtell	2013	67
15	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer Cancer Discovery ·Aphrothiti J. Hanrahan, Nikolaus Schultz, Maggie L. Westfal, Rita A. Sakr, Dilip D. Giri, Stefano Scarperi, Manickam Janikariman, Narciso Olvera, Ellen V. Stevens, Qing‐Bai She, Carol Aghajanian, Tari A. King, Elisa de Stanchina, David R. Spriggs, Adriana Heguy, Barry S. Taylor, Chris Sander, Neal Rosen, Douglas A. Levine, David B. Solit	2011	88
16	Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen Clinical Cancer Research ·Alena A. Chekmasova, Thapi D. Rao, Yan Nikhamin, Kay J. Park, Douglas A. Levine, David R. Spriggs, Renier J. Brentjens	2010	138
17	The 6q22.33 Locus and Breast Cancer Susceptibility Cancer Epidemiology Biomarkers & Prevention ·Tomas Kirchhoff, Zhang-qun Chen, Bert Gold, Prodipto Pal, Mia M. Gaudet, Kristi Kosarin, Douglas A. Levine, Peter K. Gregersen, Sara Spencer, Megan Harlan, Mark E. Robson, Robert J. Klein, Clifford A. Hudis, Larry Norton, Michael Dean, Kenneth Offit	2009	15
18	Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clinical Cancer Research ·Andrew Berchuck, Edwin S. Iversen, Jingqin Luo, Jennifer Clarke, Hisani N. Horne, Douglas A. Levine, Jeff Boyd, Miguel A. Alonso, Angeles Alvarez Secord, Marcus Q. Bernardini, Jason C. Barnett, Todd Boren, Susan K. Murphy, Holly K. Dressman, Jeffrey R. Marks, Johnathan M. Lancaster	2009	60
19	A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer Cancer Research ·Tomás Bonome, Douglas A. Levine, Joanna H. Shih, Mike Randonovich, Cindy A. Pise-Masison, Faina Bogomolniy, Laurent Ozbun, John Brady, J. Carl Barrett, Jeff Boyd, Michael J. Birrer	2008	325
20	Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer Journal of Clinical Oncology ·Dimitrios Spentzos, Douglas A. Levine, Shakirahmed Kolia, Hasan H. Otu, Jeff Boyd, Towia A. Libermann, Stephen A. Cannistra	2005	109

About Douglas A. Levine

Douglas A. Levine is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Cancer Research, Oncology and Genetics, having authored 256 papers that have together received 22.4k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (124 papers), Endometrial and Cervical Cancer Treatments (62 papers), BRCA gene mutations in cancer (40 papers), Intraperitoneal and Appendiceal Malignancies (35 papers), Cancer Genomics and Diagnostics (33 papers), Cancer-related molecular mechanisms research (27 papers), Uterine Myomas and Treatments (20 papers) and PARP inhibition in cancer therapy (19 papers). The work is most often cited by research in Reproductive Medicine (7.3k citations), Obstetrics and Gynecology (4.5k citations), Cancer Research (6.3k citations), Oncology (6.7k citations) and Pulmonary and Respiratory Medicine (5.4k citations). Douglas A. Levine has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Gad Getz, Peter W. Laird, Hui Shen, Scott L. Carter, Nadeem R. Abu‐Rustum, Gordon B. Mills, Richard R. Barakat, Emmanuel Martínez, Rahulsimham Vegesna and Katherine Stemke‐Hale. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact